Search Results - "Hervonen, P."

2556 Biweekly cabazitaxel is a safe treatment option for metastatic castration resistant prostate cancer (mCRPC) patients postdocetaxel - Prosty II trial by Kellokumpu-Lehtinen, P.L, Martila, T, Hervonen, P, Kataja, V, Utriainen, T, Luukkaa, M, Leskinen, M, Pulkkanen, K, Taalikka, M, Kautio, A.L

Get full text

POSC66 Cost-Effectiveness of Avelumab as First-Line Maintenance Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Finland by Karttunen, E, Jaaskelainen, S, Hervonen, P, Chang, J, Kearney, M

Get full text

Clinical utility of complex multi-platform profiling in metastatic cancer patients by Garcia Foncillas, J., Aftimos, P.G., Barthelemy, P., Bellmunt, J., Berchem, G., Camps, C., de las Peñas, R., Finzel, A., Hervonen, J.P., Joensuu, T., Kong, A., Mackay, J., Mikropoulos, C., Mokbel, K., Mouysset, J.-L., Perren, T.-J., Guitti, G., Laes, J.-F.

Get full text

FINPRO – a nationwide registry study on localized prostate cancer in Finland by Murtola, T., Hakkarainen, T., Lahelma, M., Pennanen, P., Pietilä, M., Hervonen, P., Kääriäinen, O., Minn, H., Nykopp, T., Ronkainen, H., Ettala, O., Rannikko, A.S.

Get full text

A0828 - FINPRO – a nationwide registry study on localized prostate cancer in Finland by Murtola, T., Hakkarainen, T., Lahelma, M., Pennanen, P., Pietilä, M., Hervonen, P., Kääriäinen, O., Minn, H., Nykopp, T., Ronkainen, H., Ettala, O., Rannikko, A.S.

Get full text

2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial by Kellokumpu-Lehtinen, Pirkko-Liisa, Prof, Harmenberg, Ulrika, MD, Joensuu, Timo, MD, McDermott, Ray, MD, Hervonen, Petteri, MD, Ginman, Claes, MD, Luukkaa, Marjaana, MD, Nyandoto, Paul, MD, Hemminki, Akseli, Prof, Nilsson, Sten, Prof, McCaffrey, John, Prof, Asola, Raija, MD, Turpeenniemi-Hujanen, Taina, Prof, Laestadius, Fredrik, MD, Tasmuth, Tiina, MD, Sandberg, Katinka, MD, Keane, Maccon, MD, Lehtinen, Ilari, BSc, Luukkaala, Tiina, MSc, Joensuu, Heikki, Prof

“…Summary Background Docetaxel administered every 3 weeks is a standard treatment for castration-resistant advanced prostate cancer. We hypothesised that…”
Get full text

4019 POSTER Phase III, randomized, open-label study of triweekly docetaxel (tT) vs. biweekly docetaxel (bT) as treatment for advanced hormone refractory prostate cancer (HRPC): findings from an interim safety analysis by Kellokumpu-Lehtinen, P, Joensuu, T, Hervonen, P, Nyandoto, P, Luukkaala, T, Hemminki, A, Asola, R, Luukkaa, M, Lehtinen, I, Joensuu, H

Get full text

Incidence, mortality and relative survival of patients with cancer of the bladder and upper urothelial tract in the Nordic countries between 1990 and 2019 by Karttunen, Eemil, Hervonen, Petteri, Hosseini Aliabad, Abolfazl, Oldenburg, Jan, Pappot, Helle, Sairanen, Jukka, Støvring, Henrik, Vásquez, Juan Luis, Bergman, Suzanne, Magnussen, Gry, Norremark, Pernille, Thoresen, Steinar, Ullén, Anders

“…To understand the potential impact of new treatment options for urinary tract cancer, recent population trends in incidence, mortality and survival should be…”
Get more information

Docetaxel-ifosfamide combination chemotherapy in patients with metastatic hormone-refractory prostate cancer: a phase I pharmacokinetic study by Hervonen, P, Jekunen, A, Lefebvre, P, Kellokumpu-Lehtinen, P

“…This phase I study was designed to evaluate the activity toxicity and pharmacokinetics of docetaxel combined with ifosfamide in the treatment of…”
Get more information

Phase III, randomized, open-label study of triweekly versus biweekly docetaxel (T) as a treatment for advanced hormone-refractory prostate cancer (HRPC): Final analysis of the Finnish Uro-oncological Group Study 1-2003 by Kellokumpu-Lehtinen, P., Harmenberg, U., Joensuu, T. K., McDermott, R., Hervonen, P., Ginman, C., Luukkaa, M., Nyandoto, P., Luukkaala, T., Joensuu, H.

“…Abstract only…”
Get full text

Phase III, randomized, open-label study of triweekly docetaxel versus biweekly docetaxel as treatments for advanced hormone-refractory prostate cancer: Findings from an interim safety analysis of the Finnish Uro-oncological Group Study 1-2003 by Hervonen, P., Joensuu, H., Joensuu, T. K., Nyandoto, P., Luukkaa, M., Nilsson, S., Hemminki, A. E., Asola, R., Luukkaala, T., Kellokumpu-Lehtinen, P.

“…Abstract only 129 Background: Docetaxel (T) administered at every three weeks is standard treatment for advanced HRPC. We compared 2-weekly to 3-weekly T as…”
Get full text

Triweekly docetaxel versus biweekly docetaxel as a treatment for advanced castration resistant prostate cancer: Quality of life analysis by Kellokumpu-Lehtinen, Pirkko-Liisa Irmeli, Harmenberg, Ulrika, Hervonen, Petteri, Joensuu, Timo K., McDermott, Raymond S., Ginman, Claes, Luukkaa, Marjaana, Nyandoto, Paul, Hemminki, Akseli, Nilsson, Sten, McCaffrey, John, Asola, Raija, Turpeenniemi Hujanen, Taina, Laestadius, Fredrik, Tasmuth, Tiina, Sandberg, Katinka, Keane, Maccon M., Lehtinen, Ilari, Luukkaala, Tiina, Joensuu, Heikki

“…Abstract only 23 Background: Bi-weekly docetaxel (T) with prednisone improved progression free survival and overall survival when compared with the standard…”
Get full text

1340PClinical utility of complex multi-platform profiling in metastatic cancer patients by Garcia Foncillas, J, Aftimos, P G, Barthelemy, P, Bellmunt, J, Berchem, G, Camps, C, de las Peñas, R, Finzel, A, Hervonen, J P, Joensuu, T, Kong, A, Mackay, J, Mikropoulos, C, Mokbel, K, Mouysset, J-L, Perren, T-J, Guitti, G, Laes, J-F

Get full text

A randomised dose-finding phase II study on ifosfamide in metastatic hormone-refractory prostate cancer (HRPC) by Hervonen, P, Lehtinen, T, Tammela, T L, Kellokumpu-Lehtinen, P

“…The palliative efficacy and toxicity of single-ifosfamide chemotherapy were investigated in patients with progressive metastatic hormone-refractory prostate…”
Get more information